about
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinomaPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerA high-throughput scintillation proximity-based assay for human DNA ligase IVDNA end resection by CtIP and exonuclease 1 prevents genomic instabilityProteolysis of Rad17 by Cdh1/APC regulates checkpoint termination and recovery from genotoxic stressTIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathwayRad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaksDisruption of TTDA results in complete nucleotide excision repair deficiency and embryonic lethalityThe DNA-damage response in human biology and diseaseHuman RECQ helicases: roles in DNA metabolism, mutagenesis and cancer biologySusceptibility pathways in Fanconi's anemia and breast cancerA de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancerProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsThe combined status of ATM and p53 link tumor development with therapeutic responseIdentification of a novel, widespread, and functionally important PCNA-binding motifActivation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes VirusTargeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung CancerHPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment StrategiesRole of the XPA protein in the NER pathway: A perspective on the function of structural disorder in macromolecular assemblyProtein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove AdductsInhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapyRadio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinicThe Impact of Hedgehog Signaling Pathway on DNA Repair Mechanisms in Human CancerGenotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionAtaxia-telangiectasia: future prospectsDiseases associated with defective responses to DNA damageExpression and functionality of histone H2A variants in cancerOverview of base excision repair biochemistrySapacitabine for cancerPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesNucleo-cytoplasmic shuttling of the endonuclease ankyrin repeats and LEM domain-containing protein 1 (Ankle1) is mediated by canonical nuclear export- and nuclear import signalsMechanism of ADP-ribosylation removal revealed by the structure and ligand complexes of the dimanganese mono-ADP-ribosylhydrolase DraGDouble threading through DNA: NMR structural study of a bis-naphthalene macrocycle bound to a thymine-thymine mismatchFine tuning chemotherapy to match BRCA1 statusChoices have consequences: the nexus between DNA repair pathways and genomic instability in cancerTherapy-related myeloid neoplasms - what have we learned so far?Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
P2860
Q21558626-92EF38F6-8B38-476A-BE1C-43305B584628Q24187899-7EF167AC-E267-4BD1-9750-C023D7085106Q24234893-3012A36D-E027-45A6-B882-D6A50345721CQ24300405-9297CBFB-7968-481E-AECC-E5C1D6B5928EQ24305549-3117E4FB-AC98-4912-9E31-70DE4FC4BE84Q24307983-CDA93416-7C07-4F3A-87DA-FC6FB5B66045Q24337162-B95705C6-177C-4434-B397-B7FD748C67C2Q24337442-29391DAF-DC2E-450A-82A7-FF1D35D10F71Q24339524-EC68C0C5-4201-487C-AC23-597EA5226057Q24606586-F4B5ED9A-3FFB-4CA7-B52C-9EB7EDAB1912Q24620195-84D3C710-9218-4F7F-81C9-408000649A36Q24628760-8DDF7850-CA4C-4412-9410-9B2372D37DABQ24632225-FF5E2434-71C0-428A-8F6F-6E7D0CF8E7BCQ24632628-4BDB47AC-AADD-4715-9C7F-10ACF384BD70Q24644255-84E2FCB7-87E1-4322-9C6F-8E45E32FF50BQ24652535-ACB25E77-B933-4643-A9E7-8BBF5DD538EBQ24656594-27A4F944-0D97-4297-933B-FA544F6D8D59Q26743368-22B63046-06D7-40E6-AC9F-39305B33D318Q26743378-04F76722-2F78-4427-A0B6-DAA178963F4AQ26752584-2080AA58-8B22-4662-8AA3-0C409C3E7395Q26766647-5DDE8AC0-3A87-44A2-AF67-D2F360E8706CQ26778143-932DF4A8-311D-42E9-843B-040A24D14D15Q26796576-42D4E365-681E-48C5-A723-819F37B73B3BQ26800196-0EBC5CEB-F653-4101-AE60-DECD04A033A0Q26801375-FE030A72-A60C-4080-893D-52B20D5B908AQ26851196-B2456567-71AA-43A0-A78F-465B46DC20C5Q26851765-74A9BC11-AE25-401B-9FDB-97EEA27C8635Q26863728-82F46CA9-E0A8-4CD5-898B-52399F9AC0E2Q26997852-89EC6342-8505-459A-A882-3D36DF597773Q27014044-1A623345-5437-4768-950D-2467B9DA7C2DQ27021659-B21524AA-D747-4D7A-A01D-AE28A5EDB3CDQ27024675-5F664291-0922-42CC-873B-636135E7C137Q27027503-4C997072-CEEE-4A54-959E-C928A40E5B70Q27318643-3E485F8D-C4C2-41D7-B596-7EDC261C0DBCQ27657174-8E0A4F83-B9ED-4584-B68B-AA2D8B76E06CQ27677452-329BB9E8-A97D-4240-8596-899DDE7F23F9Q27694529-5C6F9BFA-F10C-49E8-AE05-B5C7E4399037Q28066464-1C5D26DA-7C0F-4E95-8608-545DF2A342CEQ28071318-F20AE768-1CF1-491F-8CEA-C67ED492F554Q28071541-CB202A60-39D8-4552-87A8-1BA24C974334
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
DNA repair pathways as targets for cancer therapy
@ast
DNA repair pathways as targets for cancer therapy
@en
type
label
DNA repair pathways as targets for cancer therapy
@ast
DNA repair pathways as targets for cancer therapy
@en
prefLabel
DNA repair pathways as targets for cancer therapy
@ast
DNA repair pathways as targets for cancer therapy
@en
P2093
P3181
P356
P1476
DNA repair pathways as targets for cancer therapy
@en
P2093
P2888
P304
P3181
P356
10.1038/NRC2342
P407
P577
2008-03-01T00:00:00Z
P5875
P6179
1050082312